ReviewJournal of lipid research2013
Niacin, an old drug with a new twist.
Review in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 68 citations in OpenAlex.
- Combination therapy of statin and acipimox versus statin monotherapy in acute myocardial infarction with hypertriglyceridemia: a multicenter propensity score-matched analysis.Lipids in health and disease · 2026Article
- Scoping review of micronutrient imbalances, clinical manifestations, and interventions.World journal of methodology · 2025Review
- Medication effects on uric acid levels in rheumatoid arthritis studies.Clinical rheumatology · 2025Article
- Exploratory analysis of the association between dietary niacin intakes and nonalcoholic fatty liver disease among US adults: 1999-2018 data analysis from the National Health and Nutrition Examination Survey (NHANES).Journal of clinical biochemistry and nutrition · 2025Article
- Metabolic syndrome: epidemiology, mechanisms, and current therapeutic approaches.Frontiers in nutrition · 2025Review
- Relationship Between Vitamins and Diabetes.Cureus · 2023Review
- Very low HDL levels: clinical assessment and management.Archives of endocrinology and metabolism · 2023Review
- Article
- The niacin receptor HCAR2 modulates microglial response and limits disease progression in a mouse model of Alzheimer's disease.Science translational medicine · 2022Article
- Regulation of NADMetabolism: clinical and experimental · 2022Review
- GPR109A mediates the effects of hippuric acid on regulating osteoclastogenesis and bone resorption in mice.Communications biology · 2021Article
- Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities.Anatolian journal of cardiology · 2020Review
- Therapeutic management of hyperlipoproteinemia (a).Drugs in context · 2019Review
- Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain.Frontiers in pharmacology · 2018Article
- Niacin ameliorates ulcerative colitis via prostaglandin DEMBO molecular medicine · 2017Article
- Niacin Promotes Cardiac Healing after Myocardial Infarction through Activation of the Myeloid Prostaglandin DThe Journal of pharmacology and experimental therapeutics · 2017Article
- Impact of cholesterol on disease progression.BioMedicine · 2015Article
- Vitamins and type 2 diabetes mellitus.Endocrine, metabolic & immune disorders drug targets · 2015Review
- Testing cardiovascular drug safety and efficacy in randomized trials.Circulation research · 2014Review
- High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.Circulation research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Niacin (nicotinic acid) has been used for decades as a lipid-lowering drug. The clinical use of niacin to treat dyslipidemic conditions is limited by its side effects. Niacin, along with fibrates, are the only approved drugs which elevate high density lipoprotein cholesterol (HDLc) along with its effects on low density lipoprotein cholesterol (LDLc) and triglycerides. Whether niacin has a beneficial role in lowering cardiovascular risk on the background of well-controlled LDLc has not been established. In fact, it remains unclear whether niacin, either in the setting of well-controlled LDLc or in combination with other lipid-lowering agents, confers any therapeutic benefit and if so, by which mechanism. The results of recent trials reject the hypothesis that simply raising HDLc is cardioprotective. However, in the case of the clinical trials, structural limitations of trial design complicate their interpretation. This is also true of the most recent Heart Protection Study 2-Treatment of HDLc to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial in which niacin is combined with an antagonist of the D prostanoid (DP) receptor. Human genetic studies have also questioned the relationship between cardiovascular benefit and HDLc. It remains to be determined whether niacin may have clinical utility in particular subgroups, such as statin intolerant patients with hypercholesterolemia or those who cannot achieve a sufficient reduction in LDLc. It also is unclear whether a potentially beneficial effect of niacin is confounded by DP antagonism in HPS2-THRIVE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.